scholarly journals Impact of Oncological Therapy and Viscum album L Treatment on Cancer-Related Fatigue and Internal Coherence in Nonmetastasized Breast Cancer Patients

2020 ◽  
Vol 19 ◽  
pp. 153473542091721 ◽  
Author(s):  
Shiao Li Oei ◽  
Anja Thronicke ◽  
Matthias Kröz ◽  
Philipp von Trott ◽  
Friedemann Schad ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Physical Functioning ◽  
Real World ◽  
Viscum Album ◽  
Breast Cancer Patients ◽  
Cancer Related Fatigue ◽  
Eortc Qlq C30 ◽  
Internal Coherence ◽  
Eortc Qlq

Introduction: Viscum album L extracts (VA) are frequently used in integrative oncology. Aim of this study was to evaluate the impact of add-on VA applications on various patient-reported outcome measures. Methods: A longitudinal real-world study was conducted, using data from the Network Oncology clinical registry. Primary, nonmetastasized breast cancer patients treated with oncological standard therapy partly combined with VA applications were included. Internal Coherence Cancer-related Fatigue, and EORTC QLQ-C30 questionnaires were assessed at baseline and 6, 12, and 24 months later. Results: A total of 319 patients received standard oncological therapy and 40% of them additionally VA applications. After 6 and 12 months for patients treated with chemotherapy (Ctx) only a significant decline of the thermo-coherence, and worsening of fatigue was observed. For patients receiving VA applications but no Ctx, significant beneficial effects on thermo-coherence, fatigue, and seven EORTC QLQ-C30 scales were observed 24 months later. Adjusted multivariable long-term subgroup ( n = 106) regression analysis revealed that Ctx, immuno-, and endocrine therapies had a worsening of 17, 17, and 6 point changes, respectively, for EORTC QLQ-C30 fatigue ( P = .0004), while VA applications showed an improvement of 12 point change. A similar impact of improvement (add-on VA) and worsening (standard oncological treatment regimens) on EORTC QLQ-C30 insomnia ( P = .009) and physical functioning ( P = .005) were observed. Conclusions: In the present real-world study, add-on VA applications had a supportive effect on cancer-related fatigue, insomnia, physical functioning, and thermo-coherence. Thus, VA applications might be suited to alleviate symptom burden during anticancer therapy in breast cancer patients.

scholarly journals Validation of EORTC QLQ-C30 and QLQ-BR23 questionnaires in the measurement of quality of life of breast cancer patients in Singapore

2014 ◽  
Vol 1 (1) ◽  
pp. 22 ◽  
Author(s):  
TanMay Leng ◽  
SeowGek Ching ◽  
DahlianaBinte Idris ◽  
TeoLee Wah ◽  
LohSoon Yue ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Eortc Qlq C30 ◽  
Eortc Qlq

scholarly journals Reliability and validity of Amharic version of EORTC QLQ-C30 and QLQ-BR23 modules for assessing health-related quality of life among breast cancer patients in Ethiopia

2019 ◽  
Vol 17 (1) ◽  
Author(s):  
Diriba Alemayehu Gadisa ◽  
Esayas Tadesse Gebremariam ◽  
Getnet Yimer Ali
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Cancer Patients ◽  
Health Related Quality ◽  
Breast Cancer Patients ◽  
Related Quality ◽  
Eortc Qlq C30 ◽  
Health Related ◽  
Eortc Qlq

Abstract Background Breast cancer is the most common cancer among women and it affects quality of life of those women. So far, the two most frequently used tools for assessing health related quality of life in breast cancer patients, EORTC QLQ-C30 and EORTC QLQ-BR23 modules, were not validated in Ethiopia. Hence, the present study aimed to assess the psychometric properties of the tools among Ethiopian breast cancer patients. Methods Institutional based longitudinal study was conducted from January 1 to May 1, 2017 GC at only nationwide oncology center, Tikur Anbessa Specialized Hospital (TASH), Addis Ababa, Ethiopia. A total of 146 patients who visited the facility during that period, with no missing quality of life data, were selected for analysis. The psychometric properties of the EORTC QLQ-C30 and EORTC QLQ-BR23 were evaluated in terms of reliability, convergent, divergent, construct and clinical validity using SPSS version 22. Results Satisfactory internal consistency reliability (Cronbach’s α coefficients > 0.7) was confirmed, except for cognitive function (α = 0.516) of EORTC QLQ-C30 and body image (α = 0.510) of EORTC QLQ-BR23. Multiple-trait scaling analysis demonstrated a good convergent and divergent validity. No scaling errors were observed. Most items in EORTC QLQ-BR23 possessed a weak or no correlation with its own dimension in EORTC QLQ-C30 (r < 0.4) except with some of symptom scales. A statistically significant chemotherapy induced quality of life scores changes (P ≤ 0.05) were observed in all dimensions of both instruments between baseline and the end of first cycle chemotherapy, except for body image (P = 0.985) and sexual enjoyment (P = 0.817) of EORTC QLQ-BR23, indicating clinical validity. Conclusion Amharic version of the EORTC QLQ-C30 and EORTC QLQ-BR23 modules are valid and adequately reliable tool and can be used for clinical and epidemiological cancer researches to study the health related quality of life (HRQoL) of women with breast cancer in Ethiopia.

Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: Cognitive function (FACT-Cog) in breast cancer patients.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 6589-6589
Author(s):  
Alexandre Chan ◽  
Yu Lee Foo ◽  
Maung Shwe Ham Guo ◽  
Yuan Chuan Kee ◽  
Yee Pin Tan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Minimal Clinically Important Difference ◽  
Cognitive Deterioration ◽  
Size Estimation ◽  
Breast Cancer Patients ◽  
Clinically Important Difference ◽  
Patient Reported ◽  
Eortc Qlq C30 ◽  
Eortc Qlq

6589 Background: Establishing the Minimal Clinically Important Difference (MCID) is essential for interpreting the clinical relevance of patient reported outcomes. This is the first study to date to determine the MCID of FACT-Cog, a 37-item validated subjective neuropsychological instrument designed to evaluate cancer patients’ perceived cognitive deterioration on their quality of life. Methods: This prospective, observational study involved 220 breast cancer patients who have completed FACT-Cog and EORTC-QLQ-C30 at two time points: baseline and at least 3 months following chemotherapy. The MCID was computed using 3 approaches: 1) an anchor-based approach utilized the validated EORTC-QLQ-C30-Cognitive Functioning scale (CF) as the anchor for patients who showed a minimal deterioration on the CF (defined as a one-step deterioration on the CF scale); 2) a Receiver Operating Characteristic (ROC) curve was used to identify an optimal MCID cut-off point for deterioration; 3) a distribution-based approach utilized the 0.33 SD, 0.5 SD and one standard error of measurement (SEM) of the total FACT-Cog score (148 points) to estimate the MCID. Results: There was moderate correlation between the mean change scores of FACT-Cog and CF (rp= 0.43, p<0.001). The CF-anchored MCID was 9.6 points (95% CI 4.4 - 14.8). MCID derived from the ROC method was 7.5 points (AUC: 0.75; sensitivity: 75.6%; specificity: 68.8%). Using the distribution-based approach, MCID corresponding to effect sizes of 0.33SD to 0.5SD of the total FACT-Cog score ranged from 6.9 – 10.3 points and one-SEM criterion resulted in a MCID estimate of 10.6 points. Combining results from all approaches, the MCID identified for FACT-Cog ranged from 6.9 – 10.6 points (4.7% to 7.2% of total score). Conclusions: A 6.9 to 10.6 points reduction of the FACT-Cog score corresponds to the smallest clinically-relevant perceived cognitive deterioration. These estimates are important as they can facilitate the interpretation of patient-reported cognitive changes and sample size estimation in future studies.

P108 Assessement of changes in life quality of breast cancer patients under adjuvant CMF-chemotherapy by means of the EORTC QLQ-C30

1998 ◽  
Vol 34 ◽  
pp. S41-S42
Author(s):  
K. Rensing ◽  
L.V. Stockhausen ◽  
D. Wallwiener ◽  
E.-M. Grischke ◽  
G. Bastert
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Life Quality ◽  
Breast Cancer Patients ◽  
Eortc Qlq C30 ◽  
Eortc Qlq

scholarly journals The Internal Coherence of Breast Cancer Patients Is Associated with the Decision-Making for Chemotherapy and Viscum album L. Treatment

2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Shiao Li Oei ◽  
Anja Thronicke ◽  
Matthias Kröz ◽  
Cornelia Herbstreit ◽  
Friedemann Schad
Keyword(s):  
Breast Cancer ◽  
Decision Making ◽  
Cancer Patients ◽  
Treatment Decision ◽  
Viscum Album ◽  
Tumor Board ◽  
Breast Cancer Patients ◽  
Treatment Support ◽  
Decision Option ◽  
Internal Coherence

Objective. In the present observational study, the influence of internal coherence on shared decision-making for chemotherapy (CTX) and Viscum album L. extracts (VA) treatment in breast cancer patients was evaluated. Methods. Breast cancer patients with a guideline-oriented advice from the tumor board for CTX were included in the study. At first diagnosis (T0) and 6 months later (T1), a questionnaire, the internal coherence scale (ICS), was administered and evaluated. Prior to analysis, patients were classified retrospectively depending on their treatment decision. Results. 64 primary nonmetastasized breast cancer patients (median age 54.8 years, IQR: 46.3-65.3) were analyzed in this study. At T0, adjusted multivariable linear regression analyses revealed significant low ICS scores in patients rejecting CTX, especially in the ICS subscale “thermo coherence” (p = 0.006). The decision for add-on VA-therapy was associated with low scores for the ICS subscale “inner resilience coherence”, in particular low for the item “courage”. At T1, in the CTX+VA-group the thermo coherence increased significantly (p(d) < 0.01), while in contrast, in the CTX-only group the thermo coherence decreased significantly (p(d) = 0.02). Conclusion. Add-on VA-applications in CTX treatment support the thermo coherence of breast cancer patients, revealing a decision option to encourage patients to undergo CTX in combination with additional VA-treatments.

scholarly journals Female Breast Cancer Patients, Mastectomy-Related Quality of Life: Experience from Ethiopia

2020 ◽  
Vol 2020 ◽  
pp. 1-6
Author(s):  
Engida Abebe ◽  
Kassaw Demilie ◽  
Befekadu Lemmu ◽  
Kirubel Abebe
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Cancer Patients ◽  
Female Breast Cancer ◽  
Breast Cancer Patients ◽  
Related Quality ◽  
Eortc Qlq C30 ◽  
The Mean ◽  
Eortc Qlq

Background. Mastectomy is the most common form of treatment for a developing-nation woman diagnosed with breast cancer. This can have huge effect on a women’s quality of life. Objective. To assess mastectomy-related quality of life in female breast cancer patients. Materials and Methods. A facility-based cross-sectional descriptive study was conducted from February 1st to July 30th, 2018. A pretested structured data collection format was used to interview patients. The European Organization for Research and Treatment for Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and Breast Cancer-Specific (EORTC QLQ-BR23) were used to evaluate quality of life, functional capacity, and symptom scales. Data was analyzed with SPSS version 23. Results. The mean age of the 86 patients was 43.2 years (SD±11.4) and ranged from 25 to 70 years. 54.7% (47) of patient’s mastectomy was done on the right side. Based on EORTC QLQ-C30 global health status/QOL scale, the mean score was 48.3. On the evaluation of EORTC QLQ-BR23, future perspective about their health was low with a mean of 40.3 and their sexual functioning and enjoyment were significantly affected with mean scores of 85.3 and 71.2, respectively. Symptom scales were low with mean from 19.1 to 24.5. Majority (49, 57%) of respondents do not want to have breast reconstruction after mastectomy. Conclusion. Our breast cancer patients who underwent mastectomy performed poor in terms of quality of life as compared to international findings which demands attention in incorporating psychosocial aspects in the treatment plan.

scholarly journals KUALITAS HIDUP PASIEN KANKER PAYUDARA DI RSUP DR. KARIADI SEMARANG MENGGUNAKAN KUISIONER EORTC QLQ-C30

2021 ◽  
Vol 18 (01) ◽  
pp. 16
Author(s):  
Marwin Marwin ◽  
Dyah Aryani Perwitasari ◽  
Susan Fitri Candradewi ◽  
Bayu Prio Septiantoro ◽  
Fredrick Dermawan Purba
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Symptom Scale ◽  
Cross Sectional ◽  
Eortc Qlq C30 ◽  
Function Domain ◽  
Eortc Qlq

ABSTRACT Breast cancer is the most common cancer found in women and is the dominant cancer in Indonesia. Cancer treatments such as chemotherapy can affect the quality of life of patients including physical, psychological, and social. The purpose of this study is to measure the quality of life of breast cancer patients. This research used cross sectional study design. The patient quality of life was measured using the EORTC QLQ-C30 questionnaire. The subjects of this study were breast cancer patients in RSUP Dr. Kariadi Semarang meeting the inclusion criteria. The cognitive function domain, social function, emotional function, role function, and physical function were 86,15 ± 17,82; 84,10 ± 21,13; 82,56 ± 17,72; 77,95 ± 29,77; 76,72 ± 22,95, respectively. Whereas in symptom scale group from pain, fatigue, insomnia, appetite loss, financial difficulties, nausea and vomiting, constipation, dyspnea and diarrhea were 32,82 ± 30,33; 32,65 ± 21,14; 31,79 ± 34,58; 31,79 ± 32,51; 30,77 ± 32,44; 23,59 ± 25,67; 17,95 ± 30,9; 4,62 ± 14,28; 4,10 ± 13,83, respectively. For global health status / quality of life obtained 72.18 ± 18.94. The highest score on the functional scale is the cognitive function domain and the lowest score is the physical function.On the scale of symptom the domain that has the highest score is the pain domain and the lowest score is the diarrhea domain. Keywords: quality of life, breast cancer, EORTC QLQ-C30

Sign in / Sign up

Export Citation Format

Share Document